The Director General and Chief Executive Officer of the Raw Materials & Research Development Council (RMRDC), Professor ...

Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam o ...

“Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, in late first-quarter/early second-quarter 2025.

VIENTIANE: The government plans to increase crop yields, upgrade processing plants, and expand the export market with a view ...

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with ...